Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Variable Rate Preferred Portfolio PS (VRP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund basics

See More
  • Fund Family Invesco PowerShares
  • Assets Under Management 2,221,202,000
  • Shares Outstanding, K 88,600

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.90 +0.54%
on 07/30/18
25.12 -0.34%
on 08/14/18
+0.01 (+0.06%)
since 07/13/18
3-Month
24.71 +1.32%
on 06/25/18
25.30 -1.05%
on 06/15/18
+0.10 (+0.42%)
since 05/15/18
52-Week
24.71 +1.32%
on 06/25/18
26.15 -4.26%
on 09/12/17
-1.01 (-3.86%)
since 08/15/17

Most Recent Stories

More News
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018

Significant progress with RPL554 as potential treatment for COPD and CF

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

This three-way crossover study will inform design of pivotal Phase 3 trials

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma to Present at Upcoming Investor Conferences

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018

Announced positive top-line data from two Phase 2 clinical trials ahead of schedule

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma to Present at BioEURquity Europe 2018

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma Announces Departure of Chief Medical Officer

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases,...

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD

Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels

VRP : 25.03 (-0.16%)
VRNA : 12.54 (-3.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade VRP with:

Fund Summary

The PowerShares Variable Rate Preferred Portfolio is based on the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The Fund will generally invest at least 90% of its total assets in preferred securities that comprise the Index. The Index is a market capitalization-weighted...

See More

Key Turning Points

2nd Resistance Point 25.17
1st Resistance Point 25.12
Last Price 25.03
1st Support Level 25.02
2nd Support Level 24.97

See More

52-Week High 26.15
Fibonacci 61.8% 25.60
Fibonacci 50% 25.43
Fibonacci 38.2% 25.26
Last Price 25.03
52-Week Low 24.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar